Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$11,275 Mln
Revenue (TTM)
$4,268 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.6
Industry P/E
--
EV/EBITDA
53.5
Div. Yield
0 %
Debt to Equity
1.3
Book Value
$70.8
EPS
$-5.8
Face value
--
Shares outstanding
61,560,350
CFO
$7,838.78 Mln
EBITDA
$8,672.27 Mln
Net Profit
$2,353.42 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Jazz Pharmaceuticals PLC (JAZZ)
| 10.0 | -1.6 | 10.0 | 49.6 | 8.5 | 2.5 | 3.4 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Jazz Pharmaceuticals PLC (JAZZ)
| 38.0 | -22.8 | 25.0 | -22.8 | 10.6 | 20.4 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and... idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland. Address: Waterloo Exchange, Dublin, Ireland, D04 E5W7 Read more
Co-Founder, Chairman & CEO
Mr. Bruce C. Cozadd
Co-Founder, Chairman & CEO
Mr. Bruce C. Cozadd
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Jazz Pharmaceuticals PLC (JAZZ) is $186.95 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Jazz Pharmaceuticals PLC (JAZZ) has given a return of 8.51% in the last 3 years.
Since, TTM earnings of Jazz Pharmaceuticals PLC (JAZZ) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-29.11
|
2.40
|
|
2024
|
13.52
|
1.85
|
|
2023
|
20.66
|
2.29
|
|
2022
|
-44.83
|
3.26
|
|
2021
|
-23.82
|
1.98
|
The 52-week high and low of Jazz Pharmaceuticals PLC (JAZZ) are Rs 197.60 and Rs 95.49 as of 03-Apr-2026.
Jazz Pharmaceuticals PLC (JAZZ) has a market capitalisation of $ 11,275 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Jazz Pharmaceuticals PLC (JAZZ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.32
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.